Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2– advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic TNBC.
[Carrick Therapeutics]
7992332
{7992332:nan}
apa
50
1
165763
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
